Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock

May 8, 2026 by InsiderTrades.com

Key Points

Engine Capital (a >10% holder) bought 30,000 shares of Orthofix on May 7 at $12.18 and, across May 5–7, accumulated roughly 184,900 shares for about $2.23 million, raising its stake to ~3.85 million shares.
Orthofix's Q1 results modestly beat expectations with EPS of ($0.52) vs. ($0.68) and revenue of $196.7M, but the company remains unprofitable with negative margins and return on equity.
Regulatory risk from the FDA reclassification of bone growth stimulators could pressure competition and margins, and analysts currently rate the stock a consensus "Hold" with a $17.25 average price target.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) major shareholder Engine Capital Management, Lp purchased 30,000 shares of the firm's stock in a transaction dated Thursday, May 7th. The shares were purchased at an average cost of $12.18 per share, for a total transaction of $365,400.00. Following the purchase, the insider directly owned 3,848,573 shares in the company, valued at approximately $46,875,619.14. This represents a 0.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

On Wednesday, May 6th, Engine Capital Management, Lp purchased 41,946 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.23 per share, for a total transaction of $512,999.58.
On Tuesday, May 5th, Engine Capital Management, Lp purchased 112,950 shares of Orthofix Medical stock. The shares were purchased at an average cost of $11.99 per share, for a total transaction of $1,354,270.50.
On Wednesday, February 25th, Engine Capital Management, Lp purchased 13,061 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.96 per share, for a total transaction of $169,270.56.
On Tuesday, February 24th, Engine Capital Management, Lp purchased 124,797 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.55 per share, for a total transaction of $1,566,202.35.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $12.07 on Friday. The business's 50 day simple moving average is $12.20 and its 200-day simple moving average is $13.88. The firm has a market capitalization of $484.49 million, a price-to-earnings ratio of -7.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.43. Orthofix Medical Inc. has a 12 month low of $10.24 and a 12 month high of $16.99.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.16. The business had revenue of $196.71 million for the quarter, compared to analyst estimates of $196.40 million. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%. As a group, equities analysts forecast that Orthofix Medical Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Orthofix Medical

A number of large investors have recently bought and sold shares of the stock. R Squared Ltd grew its holdings in Orthofix Medical by 7.2% during the 1st quarter. R Squared Ltd now owns 13,518 shares of the medical device company's stock valued at $155,000 after buying an additional 904 shares during the last quarter. CWM LLC grew its holdings in Orthofix Medical by 99.0% during the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company's stock valued at $28,000 after buying an additional 955 shares during the last quarter. Gabelli Funds LLC grew its holdings in Orthofix Medical by 0.4% during the 4th quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company's stock valued at $3,567,000 after buying an additional 1,000 shares during the last quarter. Raymond James Financial Inc. grew its holdings in Orthofix Medical by 1.5% during the 3rd quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company's stock valued at $978,000 after buying an additional 1,000 shares during the last quarter. Finally, Amundi grew its holdings in Orthofix Medical by 2.7% during the 4th quarter. Amundi now owns 41,527 shares of the medical device company's stock valued at $630,000 after buying an additional 1,086 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on OFIX shares. Wall Street Zen lowered Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Canaccord Genuity Group lowered their target price on Orthofix Medical from $24.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. Stifel Nicolaus lowered their target price on Orthofix Medical from $22.00 to $18.00 and set a "buy" rating on the stock in a report on Monday, March 9th. TD Cowen assumed coverage on Orthofix Medical in a report on Tuesday, January 27th. They set a "hold" rating and a $14.00 target price on the stock. Finally, Barrington Research reiterated an "outperform" rating and set a $17.00 target price on shares of Orthofix Medical in a report on Friday, April 10th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $17.25.

View Our Latest Analysis on Orthofix Medical

Key Stories Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

Positive Sentiment: Engine Capital (a >10% holder) accumulated ~184,900 OFIX shares across May 5–7 (~112,950 @ $11.99, 41,946 @ $12.23, 30,000 @ $12.18), spending roughly $2.23M and raising its stake to ~3.85M shares (≈+4.98% total increase). The buy program signals confidence from a large shareholder and can be viewed as supportive for the stock. Read More.
Positive Sentiment: Q1 results beat modestly: Orthofix reported EPS of ($0.52) vs. consensus ($0.68) and revenue $196.7M roughly in line with estimates. The beat reduces near-term downside risk from guidance misses, though the company remains unprofitable with negative margins and ROE. Read More.
Neutral Sentiment: Q1 earnings call transcript is available for detail on trends, margin drivers and outlook — useful for investors assessing whether the beat reflects sustainable improvement or one-offs. Read More.
Negative Sentiment: Regulatory risk: the FDA reclassified bone growth stimulators (Orthofix’s core product area), which may raise competition and pressure margins going forward. This is a material industry/regulatory change that could weigh on revenue and profitability if reimbursement or market dynamics shift. Read More.

Orthofix Medical Company Profile

(Get Free Report)

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.